Navigation Links
ARIUS announces fourth quarter and year-end fiscal 2007 financial results
Date:1/29/2008

es.

As at November 30, 2007, the Company's cash and cash equivalents, short-term investments and working capital position were $5,635,365, $6,825,190 and $9,088,712 respectively, compared with November 30, 2006 balances of $4,077,065, $16,135,490 and $20,222,321, respectively. The Company believes that it has adequate financial resources for anticipated expenditures until the fourth quarter of fiscal 2008.

Conference Call

ARIUS will host a conference call today (Tuesday January 29, 2008 at 8:00 a.m. ET) to discuss its fourth quarter and year-end fiscal 2007 results. To access the conference call by telephone, dial 416-644-3414 or 1-800-731-6941. Please connect approximately five minutes prior to the beginning of the call to ensure participation. A live audio webcast of the conference call will be available at http://www.ariusmabs.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above website for 365 days.

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusmabs.com

Financial Information to follow:

ARIUS RESEARCH INC.

(A DEVELOPMENT STAGE COMPANY)


'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
2. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
3. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
4. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
5. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
6. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
7. ARIUS to present at Chinese Global Financial Forum
8. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
9. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
10. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
11. China Bionanometer Industries Corporation Announces Record Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , December 23, 2014 ... Algeria , out today and available for free download ... actors driving change and growth in the sector today. ... scored notable successes has been in developing a homegrown pharmaceutical ... percent local production still remains some way off. A cursory ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
(Date:12/22/2014)... 2014 The American Journal ... original research, reviews and editorials addressing developments and ... today published a provocative article exploring the role ... and potential treatment of prostate cancer. , ... proposes the possibility that there could be a ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... Trial Programs Funded Through 2009, SAN FRANCISCO, ... Ottawa, Ontario), a clinical stage biopharmaceutical company,developing a ... announced the closing of a financing transaction with,gross ... of $8 million USD.,The offering was completed without ...
... or dusts be protected by UL certified lights that have an ... of these lights available for oil rig workers and paint spray ... ... 2008 -- OSHA requirements mandate that workers exposed to flammable vapors ...
... FRANCISCO, Sept. 9 VIA Pharmaceuticals,Inc. (Nasdaq: ... development of,compounds for the treatment of cardiovascular disease, ... on Tuesday, September 16, 2008 at 12:00pm,Eastern Time ... Libby, Chief of,Cardiovascular Medicine at the Brigham and ...
Cached Biology Technology:Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director 2Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director 3Explosion Proof Fluorescent Lights Keep Paint Spray Booths and Oil Rig Workers Safe 2VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16 2VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16 3VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16 4
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased ... boosted investments in new testing and inspection technologies. ... given rise to a range of innovative test ... requirements of Generation Y, which is generally more ... a result, product development strategies of test equipment ...
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... WASHINGTON, Pa., Nov. 30, 2011 ADFLOW Health ... digital messaging focused on Consumer Health Engagement and ... screening kiosks—Personal Health Centers™—in all Rite Aid locations. ... The agreement with ADFLOW demonstrates Rite ...
... WASHINGTON, Nov. 30Ultra-tiny zinc oxide (ZnO) particles with ... the ingredients list of some commercially available sunscreen products, ... beneath the outer layer of skin. To help ... from Australia and Switzerland have developed a way to ...
... a pair of physicians at Boston University School of Medicine ... development of a test that can help diagnose membranous nephropathy ... offered in the research setting and is awaiting commercial development, ... the disease. Currently, the only way to diagnose the disease ...
Cached Biology News:ADFLOW Health Networks to Provide Blood Pressure Screening Centers at Rite Aid Pharmacies Nationwide 2Scientists use laser imaging to assess safety of zinc oxide nanoparticles in sunscreen 2BUSM researchers develop blood test to detect membranous nephropathy 2
... Competitor Assay Kits are ideal for ... binding compounds using fluorescence polarization (FP) ... of glutathione transferase to the ligand ... [PR-LBD(GST)] and a proprietary, fluorescently-tagged progesterone ...
... vectors combine the proven features of the ... and provides all of the benefits and ... vector backbone. The pTriEx vectors have been ... genes in all three expression systems. In ...
Rabbit polyclonal to Shigella Immunogen: Mixture of S. boydii, S. flexneri & S. dysenteriae....
... Cell Identification Kit. ALDEFLUORs ... substrate for the enzyme ... is highly expressed in ... making ALDH an extremely ...
Biology Products: